Drug Type Small molecule drug |
Synonyms Foslinanib, Foslinanib (USAN/INN), Trx-818 free acid + [2] |
Target- |
Mechanism Angiogenesis inhibitors, Apoptosis stimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H13FNNa2O6P |
InChIKeyHANFVYCDGRSZSD-UHFFFAOYSA-N |
CAS Registry1256037-62-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Unresectable Hepatocellular Carcinoma | Phase 2 | TW | 23 May 2022 | |
Advanced Neuroendocrine Neoplasm | Phase 2 | TW | 15 Dec 2018 | |
Gastro-Enteropancreatic Neuroendocrine Tumor | Phase 2 | TW | 15 Dec 2018 | |
Lung Cancer | Phase 2 | CN | 15 Dec 2018 | |
Neuroendocrine Carcinoma | Phase 2 | TW | 15 Dec 2018 | |
Neuroendocrine neoplasm of lung | Phase 2 | TW | 15 Dec 2018 | |
Stomach Cancer | Phase 2 | CN | 15 Dec 2018 | |
Well Differentiated Pancreatic Endocrine Tumor | Phase 2 | TW | 15 Dec 2018 | |
Advanced cancer | Phase 2 | US | 12 Jul 2018 | |
Advanced cancer | Phase 2 | TW | 12 Jul 2018 |
Phase 2 | 43 | CVM-1118 200mg BID | qaghtfdhvu(abonbfzwnl) = zxvkqasoyc defjlcmrmh (fnrivuppqr, 5.9 - 23.8) | Positive | 13 Sep 2024 | ||
Placebo | qaghtfdhvu(abonbfzwnl) = djloigrcyu defjlcmrmh (fnrivuppqr ) | ||||||
Phase 2 | 31 | CVM-1118 200 mg BID + nivolumab 240 mg Q2W | mxapruckoz(zxoioirnfd) = 12.9% yxlnkmsjvy (sfvdgicjbz ) View more | Positive | 24 May 2024 | ||
NCT03600233 (ASCO2023) Manual | Phase 2 | 21 | nrahyxbbhk(uhhbvrjwjo) = apyvnwbetb sstdnwckjx (nrffttrcyz, 14–50) View more | Positive | 31 May 2023 | ||
Phase 1 | 28 | (US) | qsmuusqiqk(gwhetfhqtt) = 2 DLTs (grade 5 dehydration and grade 3 fatigue) were reported at cohort 6 (800 mg/daily) cwmlkvigak (urlgqkwdae ) View more | Positive | 05 Jun 2017 | ||
(Taiwan) |